Responses
Clinical/translational cancer immunotherapy
Original research
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Compose a Response to This Article
Other responses
No responses have been published for this article.
